Saturday 17 October 2026
Export AORT’s income statement to Excel — free account
Artivion, Inc.
AORT Healthcare Medical Devices
Artivion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $441.3 million, up 13.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.3%, EPS fell 1,033.3%, free cash flow fell 202.5% and total debt rose 67.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for five, operating cash flow growth for three.
21.78
0.09
−0.41%
Follow AORT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 146.48 | 217.19 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.31 | 3.84 | 4.69 | 4.73 | |
P/FCF ratio |
0.00 | 164.76 | 0.00 | 147.00 | |
P/Operating CF |
(861.55) | 1,525.54 | 105.71 | 89.83 | |
P/B ratio |
2.45 | 3.91 | 4.61 | 4.56 | |
Price to Tangible BV |
0.00 | 40.08 | 54.93 | 71.79 | |
EV/Sales |
2.93 | 4.19 | 5.03 | 5.07 | |
EV/EBITDA |
30.52 | 31.66 | 39.51 | 44.00 | |
EV/Operating CF |
33.08 | 33.17 | 55.68 | 70.40 | |
EV/FCF |
(105.70) | 179.99 | (726.43) | 157.62 | |
Quick Ratio |
1.76 | 1.74 | 1.66 | 1.99 | |
Current Ratio |
3.47 | 3.86 | 3.53 | 3.93 | |
Net Debt/EBITDA |
(178.78) | 13.41 | 9.30 | 7.91 | |
Debt/Assets |
34.16% | 24.73% | 24.62% | 25.39% | |
Debt/Equity |
0.82 | 0.48 | 0.49 | 0.50 | |
Asset Turnover |
0.49 | 0.55 | 0.53 | 0.51 | |
Operating CF/Net income |
0.09 | 0.81 | 8.08 | 3.43 | |
Capex/Depreciation |
(1.59) | (1.26) | (4.78) | (0.81) | |
Interest Coverage |
(1.15) | 1.08 | 1.93 | 2.05 | |
Research and Development Expense of Revenue |
7.20% | 7.60% | 7.86% | 7.12% | |
Selling, General and Administrative Expense of Revenue |
63.48% | 52.28% | 49.00% | 50.52% | |
Intangible Assets out of Total Assets |
0.54 | 0.46 | 0.46 | 0.48 | |
Share Based Compensation of Revenue |
6.49% | 7.23% | 3.52% | 5.41% | |
Graham Net Nets |
(0.23) | (0.04) | (0.04) | (0.04) | |
Graham Number |
0.00 | 7.26 | 6.84 | 0.00 | |
Earnings Yield |
(0.27%) | 0.68% | 0.46% | (0.54%) | |
Free Cash Flow Yield |
(1.20%) | 0.61% | (0.15%) | 0.68% | |
Revenue per Share |
2.59 | 2.42 | 2.56 | 2.40 | |
Operating CF per Share |
(0.03) | 0.02 | 0.43 | 0.47 | |
Capex per Share |
(0.22) | (0.17) | (0.61) | (0.10) | |
Free Cash Flow per Share |
(0.25) | (0.14) | (0.18) | 0.37 | |
Cash per Share |
1.59 | 1.16 | 1.43 | 1.55 | |
Shareholders Equity per Share |
9.18 | 9.37 | 9.89 | 9.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.18 | 9.37 | 9.89 | 9.29 | |
Free Cash Flow |
(12.01) | (6.85) | (7.95) | 17.65 | |
Working Capital |
264.45 | 264.82 | 256.53 | 251.66 | |
Capital Expenditures |
(10.75) | (8.00) | (27.51) | (4.61) | |
Net Current Asset Value |
(254.97) | (75.17) | (78.48) | (81.47) | |
EV/EBIT |
66.85 | 51.44 | 65.81 | 83.32 | |
Capex to Sales |
0.09 | 0.07 | 0.24 | 0.04 | |
Price to Operating Income |
52.85 | 47.09 | 61.28 | 77.71 | |
| Other line items | |||||
Average Receivables |
106.01 | 100.69 | 94.79 | 87.67 | |
Average Payables |
20.15 | 15.02 | 17.01 | 13.82 | |
Average Inventory |
95.04 | 89.96 | 86.10 | 87.34 | |
Average Assets |
955.16 | 837.16 | 836.95 | 830.40 | |
Average Common Equity |
432.74 | 372.36 | 362.22 | 371.72 |
Columns are period end dates